Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company specializing in innovative solutions for obstructive sleep apnea (OSA), has announced its first-ever share repurchase program. The company's Board of Directors has authorized the repurchase of up to $150.0 million of outstanding common stock, set to expire on August 5, 2026.
CEO Tim Herbert highlighted the company's significant progress toward sustained profitability and strong revenue growth in Q2. The repurchase program reflects Inspire's financial strength and belief in its growth prospects, particularly following the recent FDA approval of the Inspire V therapy system. The company views its stock as undervalued and considers the repurchase an attractive investment opportunity.
Inspire Medical Systems, Inc. (NYSE: INSP), un'azienda di tecnologia medica specializzata in soluzioni innovative per l'apnea ostruttiva del sonno (OSA), ha annunciato il suo primo programma di riacquisto di azioni. Il Consiglio di Amministrazione dell'azienda ha autorizzato il riacquisto di azioni ordinarie per un massimo di 150,0 milioni di dollari, che scadrà il 5 agosto 2026.
Il CEO Tim Herbert ha messo in evidenza i significativi progressi verso una redditività sostenuta e la forte crescita dei ricavi nel secondo trimestre. Il programma di riacquisto riflette la solidità finanziaria di Inspire e la sua fiducia nelle prospettive di crescita, in particolare dopo l'approvazione recente da parte della FDA del sistema di terapia Inspire V. L'azienda considera le sue azioni come sottovalutate e ritiene il riacquisto un'opportunità di investimento attraente.
Inspire Medical Systems, Inc. (NYSE: INSP), una empresa de tecnología médica especializada en soluciones innovadoras para la apnea obstructiva del sueño (OSA), ha anunciado su primer programa de recompra de acciones. La Junta Directiva de la empresa ha autorizado el recompra de hasta 150 millones de dólares en acciones ordinarias, que vencerá el 5 de agosto de 2026.
El CEO Tim Herbert destacó el significativo progreso hacia la rentabilidad sostenida y el fuerte crecimiento de los ingresos en el segundo trimestre. El programa de recompra refleja la fortaleza financiera de Inspire y su confianza en sus perspectivas de crecimiento, especialmente tras la reciente aprobación de la FDA del sistema de terapia Inspire V. La empresa ve sus acciones como subvaloradas y considera la recompra como una oportunidad de inversión atractiva.
인스파이어 메디컬 시스템즈, Inc. (NYSE: INSP)는 폐쇄성 수면 무호흡증 (OSA)을 위한 혁신적인 솔루션을 전문으로 하는 의료 기술 회사로서 최초의 주식 매입 프로그램을 발표했습니다. 회사의 이사회는 1억 5천만 달러의 자사 보통주를 매입할 수 있도록 승인하였으며, 이 프로그램은 2026년 8월 5일에 만료됩니다.
CEO 팀 허버트는 두 번째 분기에서의 지속 가능한 수익성에 대한 상당한 진전과 강력한 수익 성장에 대해 강조했습니다. 매입 프로그램은 인스파이어의 재정적 강점을 반영하며, 최근 FDA의 인스파이어 V 치료 시스템 승인 이후 성장 전망에 대한 신뢰를 보여줍니다. 이 회사는 자사의 주식을 저평가되었다고 보고 있으며, 매입을 매력적인 투자 기회로 간주하고 있습니다.
Inspire Medical Systems, Inc. (NYSE: INSP), une entreprise de technologie médicale spécialisée dans des solutions innovantes pour l'apnée obstructive du sommeil (OSA), a annoncé son tout premier programme de rachat d'actions. Le Conseil d'administration de l'entreprise a autorisé le rachat de jusqu'à 150 millions de dollars d'actions ordinaires en circulation, qui expirera le 5 août 2026.
Le PDG Tim Herbert a souligné les progrès significatifs vers une rentabilité durable et la forte croissance des revenus au deuxième trimestre. Le programme de rachat reflète la solidité financière d'Inspire et sa confiance dans ses perspectives de croissance, en particulier après l'approbation récente par la FDA du système de thérapie Inspire V. L'entreprise considère ses actions comme sous-évaluées et considère le rachat comme une opportunité d'investissement attrayante.
Inspire Medical Systems, Inc. (NYSE: INSP), ein Medizintechnikunternehmen, das sich auf innovative Lösungen für obstruktive Schlafapnoe (OSA) spezialisiert hat, hat sein erstes Aktienrückkaufprogramm angekündigt. Der Vorstand des Unternehmens hat den Rückkauf von bis zu 150 Millionen Dollar an ausgegebenen Stammaktien genehmigt, das am 5. August 2026 ausläuft.
CEO Tim Herbert hob den deutlichen Fortschritt in Richtung nachhaltiger Rentabilität und starkes Umsatzwachstum im zweiten Quartal hervor. Das Rückkaufprogramm spiegelt die finanzielle Stärke von Inspire und das Vertrauen in die Wachstumsaussichten wider, insbesondere nach der kürzlichen FDA-Zulassung des Inspire V Therapiensystems. Das Unternehmen betrachtet seine Aktien als unterbewertet und sieht den Rückkauf als attraktive Investitionsmöglichkeit an.
- Board authorization of $150 million share repurchase program
- Significant progress toward sustained profitability in Q2
- Strong revenue growth reported
- Recent FDA approval of Inspire V therapy system
- Financial strength allowing capital return while investing in growth
- Potential reduction in cash reserves for future investments or acquisitions
Inspire Medical Systems' $150 million share repurchase program signals confidence in the company's financial health and future prospects. This move, a first for Inspire, comes on the heels of significant progress toward sustained profitability and strong revenue growth in Q2. The program's 2-year timeframe provides flexibility, allowing the company to capitalize on market opportunities.
The repurchase could potentially boost earnings per share by reducing the number of outstanding shares. However, investors should note that this could come at the expense of cash reserves that might otherwise be used for R&D or expansion. The company's belief that its stock is undervalued suggests management sees the repurchase as a strategic investment rather than just returning capital to shareholders.
The recent FDA approval of Inspire V therapy system is a significant milestone for Inspire Medical Systems. This advancement in their obstructive sleep apnea (OSA) treatment technology could be a key driver for future growth. The company's confidence in allocating
The medical device industry, particularly in sleep apnea treatment, is highly competitive. Inspire's ability to balance shareholder returns with continued innovation will be crucial. The repurchase program, coupled with their technological advancements, may enhance investor confidence in the company's long-term strategy and market potential in the expanding OSA treatment sector.
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that its Board of Directors has authorized the repurchase of up to
“I am pleased to announce our intention to purchase up to
In determining the amount of capital to allocate to share repurchases, the company considers, among other things, its historical and expected business performance and cash and liquidity position, as well as global economic and market conditions and the market price of the company’s common stock. The timing, manner, price, and amount of any repurchases under the share repurchase program are determined by the company in its discretion. Purchases may be effected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The company is not obligated to repurchase any specific number of shares and the program may be modified, suspended, or discontinued at any time. The share repurchase program will expire on August 5, 2026, subject to the earlier termination or extension by the Board, in its sole discretion and without prior notice, or until such time that the funds designated for the stock repurchase program are depleted.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding our growth prospects. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of macroeconomic trends; general and international economic, political, and other risks, including currency, inflation, stock market fluctuations and the uncertain economic environment; our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, including our next generation Inspire therapy system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
FAQ
What is the amount authorized for Inspire Medical Systems' share repurchase program?
When does Inspire Medical Systems' (INSP) share repurchase program expire?
What recent FDA approval did Inspire Medical Systems (INSP) receive?
How will Inspire Medical Systems (INSP) execute its share repurchase program?
